Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 7Completed 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 15Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9daratumumab 8atezolizumab 8Rituximab 8Capecitabine 8Lenalidomide 7Doxorubicin 7zanubrutinib 6Prednisone 6Daunorubicin 6Bortezomib 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has announcements × trastuzumab deruxtecan × Clear all
NCT04744831 2026-01-14

DESTINY-CRC02

Daiichi Sankyo

Phase 2 Completed
122 enrolled 21 charts 1 FDA
Gastrointestinal

Colorectal Neoplasms

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
292 enrolled 35 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Daiichi Sankyo

Phase 2 Completed
233 enrolled 26 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡